In this Healio Video Perspective, Baruch D. Kuppermann, MD, PhD, speaks about AVD-104, a novel approach to the management of nonexudative macular degeneration, presented at the Euretina congress in Amsterdam.
AVD-104 (Aviceda Therapeutics) is a sialic acid-coated glycomimetic nanoparticle with a dual mechanism of action. In addition to inhibiting complement cascade amplification, it repolarizes proinflammatory macrophages to their resolution state. This novel treatment target for geographic atrophy also addresses the inflammatory component of neovascular AMD.
Kuppermann explains in detail the